The United States District Courts now hear a large number of patent cases with a  heavy docket of pharmaceutical and other chemical patent cases. The Courts regularly decides Hatch-Waxman litigation, determining whether new generic drugs can go on the market before the patent(s) on the pioneer drugs expire. The statutory scheme provides a great incentive for generic pharmaceutical manufacturers to challenge patents on blockbuster drugs. Mr. Ahmed will discuss that incentive and what happens in those patent infringement suits and how the affect these valuable patents.

Hatch-Waxman: Interplay between drug development and lowering pharmaceutical costs

240th National Meeting (2010)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.